首页 > 最新文献

Intervirology最新文献

英文 中文
GSK-3β as a Potential Coordinator of Anabolic and Catabolic Pathways in Hepatitis C Virus Insulin Resistance. GSK-3β 是丙型肝炎病毒胰岛素抵抗中合成代谢和分解代谢途径的潜在协调者。
IF 4.6 4区 医学 Q3 VIROLOGY Pub Date : 2024-01-01 Epub Date: 2023-12-15 DOI: 10.1159/000535787
Gokul C Das, F Blaine Hollinger

Introduction: Chronic hepatitis C infection can result in insulin resistance (IR). We have previously shown that it occurs through the interaction of pathways for glucose homeostasis, insulin signaling, and autophagy. But it is not known how soon the pathways are activated and how IR is related to the signals generated by catabolic and anabolic conditions occurring in infected cells. We have extended our studies to a cell culture system mimicking acute infection and to downstream pathways involving energy-sensor AMPK and nutrient-sensor mTOR that are active in catabolic and anabolic processes within the infected cells.

Methods: Huh7 liver cells in culture were infected with hepatitis C virus (HCV). We performed proteomics analysis of key proteins in infected cells by Western blotting and IP experiments, with or without IFNα exposure as a component of conventional therapeutic strategy.

Results: We present evidence that (a) IRS-1 Ser312, Beclin-1, protein conjugate Atg12-Atg5 or GS Ser641 are up-regulated early in infection presumably by activating the same pathways as utilized for persistent infection; (b) Bcl-XL, an inhibitor of both autophagy and apoptosis, is present in a core complex with IRS-1 Ser312 and Beclin-1 during progression of IR; (c) AMPK level remains about the same in infected cells where it is activated by phosphorylation at Thr172 concomitant with increased autophagy, a hallmark of catabolic conditions; (d) an mTOR level that promotes anabolism is increased rather than decreased under an expanded autophagy; (e) hypophosphorylation of translational repressor 4E-BP1 downstream of mTOR is suggestive of reduced protein synthesis; and (f) β-catenin, is up-regulated but not phosphorylated suggesting indirectly our previous contention that its kinase, GSK-3β, is mostly in an inactive state.

Conclusion: We report that in the development of IR following chronic infection, anabolic and catabolic pathways are activated early, and the metabolic interaction occurs possibly in a core complex with IRS-1 Ser312, Beclin-1, and autophagy inhibitor Bcl-XL. Induction of autophagy is usually controlled by a two-edged mechanism acting in opposition under anabolic and catabolic conditions by AMPK/mTOR/4E-BP1 pathway with GSK-3β-mediated feedback loops. However, we have observed an up-regulation of mTOR along with an up-regulation of AMPK caused by HCV infection is a deviation from the normal scenario described above which might be of therapeutic interest.

简介:慢性 HCV 感染会通过葡萄糖平衡、胰岛素信号传导和自噬等途径的相互作用导致胰岛素抵抗(IR)。目前尚不清楚这些途径多久会被激活,以及胰岛素抵抗与感染细胞内分解代谢和合成代谢条件产生的信号有何关系。我们将研究扩展到模拟急性感染的细胞培养系统,以及涉及能量传感器 AMPK 和营养传感器 mTOR 的下游通路,这些通路在感染细胞内的分解代谢和合成代谢过程中十分活跃。方法:Huh7 肝细胞感染了 HCV,我们通过 Western 印迹和 IP 实验对感染细胞中的关键蛋白进行了蛋白质组学分析:结果:我们发现,IRS-1 Ser312、Beclin-1、蛋白共轭物 Atg12-Atg5 或 GS Ser641 在感染早期通过激活用于持续感染的相同途径而上调;Bcl-XL是自噬和细胞凋亡的抑制剂,在IR进展过程中与IRS-1 Ser312和Beclin-1形成核心复合物;AMPK水平在感染细胞中保持不变,它通过Thr172处的磷酸化被激活,同时自噬增加,这是分解代谢的标志;mTOR下游的翻译抑制因子4E-BP1磷酸化不足,表明蛋白质合成减少;β-catenin上调但未磷酸化,间接表明我们之前的论点,即其激酶GSK-3β大多处于非活性状态。讨论/结论:我们报告说,在慢性感染后IR的发展过程中,合成代谢和分解代谢途径在早期就被激活,代谢相互作用可能发生在与IRS-1 Ser312、Beclin-1和自噬抑制剂BcL-XL的核心复合物中。自噬的诱导通常由一个双刃机制控制,在合成代谢和分解代谢条件下,AMPK/mTOR/4E-BP1 通路与 GSK-3β 介导的回馈回路对立作用。然而,我们观察到,HCV 感染导致的 mTOR 上调和 AMPK 上调偏离了上述正常情况,这可能具有治疗意义。
{"title":"GSK-3β as a Potential Coordinator of Anabolic and Catabolic Pathways in Hepatitis C Virus Insulin Resistance.","authors":"Gokul C Das, F Blaine Hollinger","doi":"10.1159/000535787","DOIUrl":"10.1159/000535787","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic hepatitis C infection can result in insulin resistance (IR). We have previously shown that it occurs through the interaction of pathways for glucose homeostasis, insulin signaling, and autophagy. But it is not known how soon the pathways are activated and how IR is related to the signals generated by catabolic and anabolic conditions occurring in infected cells. We have extended our studies to a cell culture system mimicking acute infection and to downstream pathways involving energy-sensor AMPK and nutrient-sensor mTOR that are active in catabolic and anabolic processes within the infected cells.</p><p><strong>Methods: </strong>Huh7 liver cells in culture were infected with hepatitis C virus (HCV). We performed proteomics analysis of key proteins in infected cells by Western blotting and IP experiments, with or without IFNα exposure as a component of conventional therapeutic strategy.</p><p><strong>Results: </strong>We present evidence that (a) IRS-1 Ser312, Beclin-1, protein conjugate Atg12-Atg5 or GS Ser641 are up-regulated early in infection presumably by activating the same pathways as utilized for persistent infection; (b) Bcl-XL, an inhibitor of both autophagy and apoptosis, is present in a core complex with IRS-1 Ser312 and Beclin-1 during progression of IR; (c) AMPK level remains about the same in infected cells where it is activated by phosphorylation at Thr172 concomitant with increased autophagy, a hallmark of catabolic conditions; (d) an mTOR level that promotes anabolism is increased rather than decreased under an expanded autophagy; (e) hypophosphorylation of translational repressor 4E-BP1 downstream of mTOR is suggestive of reduced protein synthesis; and (f) β-catenin, is up-regulated but not phosphorylated suggesting indirectly our previous contention that its kinase, GSK-3β, is mostly in an inactive state.</p><p><strong>Conclusion: </strong>We report that in the development of IR following chronic infection, anabolic and catabolic pathways are activated early, and the metabolic interaction occurs possibly in a core complex with IRS-1 Ser312, Beclin-1, and autophagy inhibitor Bcl-XL. Induction of autophagy is usually controlled by a two-edged mechanism acting in opposition under anabolic and catabolic conditions by AMPK/mTOR/4E-BP1 pathway with GSK-3β-mediated feedback loops. However, we have observed an up-regulation of mTOR along with an up-regulation of AMPK caused by HCV infection is a deviation from the normal scenario described above which might be of therapeutic interest.</p>","PeriodicalId":14547,"journal":{"name":"Intervirology","volume":" ","pages":"6-18"},"PeriodicalIF":4.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10794973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138797298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanoparticles with a Lipid Core Can Enhance the Infection of Epithelial Cells with an Enterovirus. 以脂质为核心的纳米颗粒可增强肠道病毒对上皮细胞的感染。
IF 3.2 4区 医学 Q3 VIROLOGY Pub Date : 2024-01-01 Epub Date: 2024-07-26 DOI: 10.1159/000539601
Inès Vergez, Magloire Pandoua Nekoua, Cédric Rubrecht, François Fasquelle, Angelo Scuotto, Enagnon Kazali Alidjinou, Didier Betbeder, Didier Hober

Introduction: The effect of maltodextrin-based nanoparticles with an anionic phospholipid core (lipid-based nanoparticles [NPLs]) on the infection of a human tumoral cell line with poliovirus (PV) has been studied.

Methods: NPLs were synthesized and associated with the PV type 1 Sabin strain, and the formulations were characterized. PV and PV/NPL formulations were inoculated to HEp-2 cells.

Results: The surface charge and the diameter of PV/NPL formulation suggest that viral particles were adsorbed onto NPLs. When HEp-2 cells were inoculated with 1 tissue culture 50% infectious dose/mL PV associated with NPLs, the cytopathic effect appeared obvious; the levels of the infectious titer of culture supernatants and the proportion of VP1-positive cells were higher. The level of intracellular viral RNA extracted from HEp-2 cells inoculated with PV/NPL formulation was higher as well.

Conclusion: These results show that NPLs can enhance the infection with a virus and suggest that they might be used in virotherapy to increase the virus-mediated lysis of tumor cells.

导言:研究了以麦芽糊精为基础、以阴离子磷脂为核心的纳米颗粒(NPLs)对脊髓灰质炎病毒(PV)感染人类肿瘤细胞系的影响:方法:合成了与 1 型 Sabin 株脊髓灰质炎病毒相关的 NPLs,并对其配方进行了表征。将 PV 和 PV/NPL 配方接种到 HEp-2 细胞中:结果:PV/NPL 配方的表面电荷和直径表明病毒颗粒被吸附在 NPL 上。当 HEp-2 细胞接种 1 TCID50/mL PV 与 NPLs 时,细胞病理效应明显;培养上清中的感染滴度水平和 VP1 阳性细胞比例较高。从接种了 PV/NPL 配方的 HEp-2 细胞中提取的细胞内病毒 RNA 水平也较高:这些结果表明,NPLs 能增强病毒感染,并表明它们可用于病毒疗法,以增加病毒介导的肿瘤细胞裂解。
{"title":"Nanoparticles with a Lipid Core Can Enhance the Infection of Epithelial Cells with an Enterovirus.","authors":"Inès Vergez, Magloire Pandoua Nekoua, Cédric Rubrecht, François Fasquelle, Angelo Scuotto, Enagnon Kazali Alidjinou, Didier Betbeder, Didier Hober","doi":"10.1159/000539601","DOIUrl":"10.1159/000539601","url":null,"abstract":"<p><strong>Introduction: </strong>The effect of maltodextrin-based nanoparticles with an anionic phospholipid core (lipid-based nanoparticles [NPLs]) on the infection of a human tumoral cell line with poliovirus (PV) has been studied.</p><p><strong>Methods: </strong>NPLs were synthesized and associated with the PV type 1 Sabin strain, and the formulations were characterized. PV and PV/NPL formulations were inoculated to HEp-2 cells.</p><p><strong>Results: </strong>The surface charge and the diameter of PV/NPL formulation suggest that viral particles were adsorbed onto NPLs. When HEp-2 cells were inoculated with 1 tissue culture 50% infectious dose/mL PV associated with NPLs, the cytopathic effect appeared obvious; the levels of the infectious titer of culture supernatants and the proportion of VP1-positive cells were higher. The level of intracellular viral RNA extracted from HEp-2 cells inoculated with PV/NPL formulation was higher as well.</p><p><strong>Conclusion: </strong>These results show that NPLs can enhance the infection with a virus and suggest that they might be used in virotherapy to increase the virus-mediated lysis of tumor cells.</p>","PeriodicalId":14547,"journal":{"name":"Intervirology","volume":" ","pages":"99-105"},"PeriodicalIF":3.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141788054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Characterization of Enteric Viruses Causing Acute Gastroenteritis among Children under 5 Years Old in Distrito Central, Honduras. 洪都拉斯中央区 5 岁以下儿童急性肠胃炎的肠道病毒分子特征。
IF 3.2 4区 医学 Q3 VIROLOGY Pub Date : 2024-01-01 Epub Date: 2024-07-09 DOI: 10.1159/000540253
Jafet Ortiz-Quintero, Yessy Cabrera, Lurys Bourdett-Stanziola, Annabelle Ferrera

Introduction: Diarrheal diseases constitute a significant public health problem in terms of mortality and morbidity. In Honduras and around the world, RVs have consistently emerged as the single most important etiologic agent in acute childhood diarrhea. However, other viruses, such as NoVs and HAstVs, have also been shown to be responsible for viral gastroenteritis. Unfortunately, the country has limited information concerning the etiologic role of these viral agents in acute gastroenteritis. This study investigated the frequency, genotypes, and epidemiological characteristics of RV-A, NoVs, and HAstVs among children under 5 years old in Distrito Central, Honduras.

Methods: Stool samples and their corresponding epidemiological data were collected from children with acute gastroenteritis in three healthcare centers in Distrito Central. All samples were screened by immunoassays for RV-A and HAstVs. RV-A-positive samples were molecularly characterized by RT-PCR and genotyping assays. RT-PCR was also applied to confirm HAstVs positivity and to detect NoVs, followed by nucleotide sequencing to assign their genotypes.

Results: Our results show that at least one viral agent was detected in 31% of the children. The frequency of RV-A, NoVs, and HAstVs was 14%, 13%, and 5%, respectively. The most frequent RV-A genotype was G2P[4], occurring in 93% of cases. 92.3% of NoVs-positive samples belonged to genogroup II, with GII.4 and GII.16 being the most common. HAstVs were clustered into three genotypes: HAstV-1, HAstV-2, and HAstV-8. Only one sample showed coinfection with NoVs and HAstVs.

Conclusion: This comprehensive molecular and epidemiological characterization of enteric viruses demonstrates the vast diversity of these agents and describes for the first time NoVs and HAstVs as causative agents of acute childhood gastroenteritis in Distrito Central, Honduras. This suggests that further in-depth studies of the pediatric population are necessary to develop and implement effective preventive and control measures in the country.

导言:就死亡率和发病率而言,腹泻疾病是一个重大的公共卫生问题。在洪都拉斯和世界各地,RV 一直是儿童急性腹泻最重要的病原体。然而,其他病毒,如 NoVs 和 HAstVs,也被证明是病毒性肠胃炎的病原体。遗憾的是,我国对这些病毒在急性肠胃炎中的致病作用了解有限。本研究调查了洪都拉斯中央区 5 岁以下儿童中 RV-A、NoVs 和 HAstVs 的频率、基因型和流行病学特征:方法:在中央区的三个医疗中心收集急性肠胃炎患儿的粪便样本及其相应的流行病学数据。所有样本均通过免疫测定法检测 RV-A 和 HAstVs。通过 RT-PCR 和基因分型检测对 RV-A 阳性样本进行分子鉴定。RT-PCR 也用于确认 HAstVs 阳性和检测 NoVs,然后进行核苷酸测序以确定其基因型:结果:我们的结果显示,31%的儿童至少检测到一种病毒病原体。RV-A、NoVs 和 HAstVs 的频率分别为 14%、13% 和 5%。最常见的 RV-A 基因型是 G2P[4],出现在 93% 的病例中。92.3%的NoVs阳性样本属于基因组II,其中GII.4和GII.16最为常见。HAstV 可分为三种基因型:HAstV-1、HAstV-2 和 HAstV-8。只有一个样本同时感染了 NoVs 和 HAstVs:此次对肠道病毒的分子和流行病学特征的全面分析表明了这些病原体的巨大多样性,并首次描述了洪都拉斯中央区急性儿童肠胃炎的致病病原体 NoVs 和 HAstVs。这表明,有必要对儿科人群进行进一步的深入研究,以便在该国制定和实施有效的预防和控制措施。
{"title":"Molecular Characterization of Enteric Viruses Causing Acute Gastroenteritis among Children under 5 Years Old in Distrito Central, Honduras.","authors":"Jafet Ortiz-Quintero, Yessy Cabrera, Lurys Bourdett-Stanziola, Annabelle Ferrera","doi":"10.1159/000540253","DOIUrl":"10.1159/000540253","url":null,"abstract":"<p><strong>Introduction: </strong>Diarrheal diseases constitute a significant public health problem in terms of mortality and morbidity. In Honduras and around the world, RVs have consistently emerged as the single most important etiologic agent in acute childhood diarrhea. However, other viruses, such as NoVs and HAstVs, have also been shown to be responsible for viral gastroenteritis. Unfortunately, the country has limited information concerning the etiologic role of these viral agents in acute gastroenteritis. This study investigated the frequency, genotypes, and epidemiological characteristics of RV-A, NoVs, and HAstVs among children under 5 years old in Distrito Central, Honduras.</p><p><strong>Methods: </strong>Stool samples and their corresponding epidemiological data were collected from children with acute gastroenteritis in three healthcare centers in Distrito Central. All samples were screened by immunoassays for RV-A and HAstVs. RV-A-positive samples were molecularly characterized by RT-PCR and genotyping assays. RT-PCR was also applied to confirm HAstVs positivity and to detect NoVs, followed by nucleotide sequencing to assign their genotypes.</p><p><strong>Results: </strong>Our results show that at least one viral agent was detected in 31% of the children. The frequency of RV-A, NoVs, and HAstVs was 14%, 13%, and 5%, respectively. The most frequent RV-A genotype was G2P[4], occurring in 93% of cases. 92.3% of NoVs-positive samples belonged to genogroup II, with GII.4 and GII.16 being the most common. HAstVs were clustered into three genotypes: HAstV-1, HAstV-2, and HAstV-8. Only one sample showed coinfection with NoVs and HAstVs.</p><p><strong>Conclusion: </strong>This comprehensive molecular and epidemiological characterization of enteric viruses demonstrates the vast diversity of these agents and describes for the first time NoVs and HAstVs as causative agents of acute childhood gastroenteritis in Distrito Central, Honduras. This suggests that further in-depth studies of the pediatric population are necessary to develop and implement effective preventive and control measures in the country.</p>","PeriodicalId":14547,"journal":{"name":"Intervirology","volume":" ","pages":"83-98"},"PeriodicalIF":3.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11326528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Fitness of Molnupiravir-Signed SARS-CoV-2 Variants: Imputation Analysis Based on Prescription Counts and Global Initiative on Sharing All Influenza Data Analyses by Country. molnupiravir签名SARS-CoV-2变体的适应性:基于处方数的估算分析和按国家分列的GISAID分析。
IF 3.2 4区 医学 Q3 VIROLOGY Pub Date : 2024-01-01 Epub Date: 2024-11-08 DOI: 10.1159/000540282
Daniele Focosi, Dave McNally, Fabrizio Maggi

Introduction: Molnupiravir is one of the oral direct-acting antivirals against SARS-CoV-2, largely deployed during the COVID-19 pandemic since the 2022 Omicron wave. While efficacy has been questioned in post-marketing clinical trials (leading to the EMA withdrawing its authorization), growing concerns have mounted regarding its possible mutagenic effects on the virus. While it has been assumed that either all the host viral load was cleared by the drug or drug-generated variants were not fit enough to survive, several lineages with a high transition/transversion ratio (a signature of molnupiravir action) have been recently reported from GISAID.

Methods: We report here a systematic analysis of the GISAID database for sequences showing a molnupiravir signature, exposing a public web-based interface (https://ukcovid.xyz/molnupiravir/), and performing an imputation analysis based on per-country prescription (corrected by sequencing).

Results: Our analysis confirms a direct correlation between the number of molnupiravir courses and the number of mutationally signed sequences deposited in GISAID in individual countries.

Conclusions: Molnupiravir can generate fit SARS-CoV-2 variants that transmit in the general population.

简介莫能吡韦是抗击 SARS-CoV-2 的口服直接作用抗病毒药物之一,自 2022 年 Omicron 疫潮以来,在 COVID-19 大流行期间主要使用莫能吡韦。虽然在上市后的临床试验中疗效受到质疑(导致欧洲药品管理局撤销其授权),但人们越来越担心它对病毒可能产生的诱变作用。人们一直认为,要么是药物清除了所有宿主病毒载量,要么是药物产生的变异体不足以存活,但最近 GISAID 报告了几种具有高过渡/转化比(molnupiravir 作用的标志)的病毒系:我们在此报告对GISAID数据库中显示出molnupiravir特征的序列进行了系统分析,并公开了一个基于网络的界面(https://ukcovid.xyz/molnupiravir/ ),还根据各国处方(通过测序校正)进行了估算分析:结果:我们的分析证实,各个国家的莫仑吡韦疗程数与存入 GISAID 的变异签名数之间存在直接关联:结论:莫鲁吡拉韦能产生适合在普通人群中传播的 SARS-CoV-2 变异株。
{"title":"The Fitness of Molnupiravir-Signed SARS-CoV-2 Variants: Imputation Analysis Based on Prescription Counts and Global Initiative on Sharing All Influenza Data Analyses by Country.","authors":"Daniele Focosi, Dave McNally, Fabrizio Maggi","doi":"10.1159/000540282","DOIUrl":"10.1159/000540282","url":null,"abstract":"<p><strong>Introduction: </strong>Molnupiravir is one of the oral direct-acting antivirals against SARS-CoV-2, largely deployed during the COVID-19 pandemic since the 2022 Omicron wave. While efficacy has been questioned in post-marketing clinical trials (leading to the EMA withdrawing its authorization), growing concerns have mounted regarding its possible mutagenic effects on the virus. While it has been assumed that either all the host viral load was cleared by the drug or drug-generated variants were not fit enough to survive, several lineages with a high transition/transversion ratio (a signature of molnupiravir action) have been recently reported from GISAID.</p><p><strong>Methods: </strong>We report here a systematic analysis of the GISAID database for sequences showing a molnupiravir signature, exposing a public web-based interface (<ext-link ext-link-type=\"uri\" xlink:href=\"https://ukcovid.xyz/molnupiravir/\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">https://ukcovid.xyz/molnupiravir/</ext-link>), and performing an imputation analysis based on per-country prescription (corrected by sequencing).</p><p><strong>Results: </strong>Our analysis confirms a direct correlation between the number of molnupiravir courses and the number of mutationally signed sequences deposited in GISAID in individual countries.</p><p><strong>Conclusions: </strong>Molnupiravir can generate fit SARS-CoV-2 variants that transmit in the general population.</p>","PeriodicalId":14547,"journal":{"name":"Intervirology","volume":" ","pages":"114-118"},"PeriodicalIF":3.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Biological Mechanisms of Action of Chrysophanol in Hepatic Stellate Cells Activated by Hepatic B Virus X Based on Network Pharmacology. 基于网络药理学的大黄酚对乙型肝炎病毒激活的肝星状细胞作用的分子生物学机制
IF 3.2 4区 医学 Q3 VIROLOGY Pub Date : 2024-01-01 Epub Date: 2024-12-06 DOI: 10.1159/000542355
Chih-Hung Lin, Ching-Feng Cheng, Yi-Shiou Chiou, Inga Wang, Chan-Yen Kuo

Introduction: Chrysophanol (Cho) is a natural anthraquinone with biological effects such as inducing ferroptosis and anticancer activity. The hepatitis B virus X protein (HBx) is essential for HBV replication. We aimed to identify the key pathways in HBx-induced hepatic stellate cell (HSC) activation and to characterize the potential mechanisms of action of Cho against liver fibrosis.

Methods: HSC-T6 cells were transfected with FLAG (control group) or FLAG-HBx (HBx group), and RNA sequencing and Western blotting analysis were conducted to assess the effects of HBx and Cho on specific molecular targets and signaling pathways.

Results: Gene ontology and pathway analyses indicated that the genes targeted by HBx participate in immunological responses, chemokine and cytokine activity, cell-substrate adhesion, extracellular matrix organization, growth factor binding, defense responses, and antigen processing and presentation. RNA-seq and Western blotting data revealed that HBx-activated HSC-T6 cells exhibited upregulated expression of mammalian target of rapamycin (mTOR), phosphorylated mTOR (p-mTOR), S6, phosphorylated S6 (p-S6), peroxisome proliferator-activated receptor (PPAR-α), phosphorylated-PPAR-α (p-PPAR-α), CYP27, α-smooth muscle actin (α-SMA), connective tissue growth factor (CTGF), and Integrin-β1, which was reversed after treatment with Cho. These results were also verified in a HBx-activated HSC-T6 and LX-2 cell model and thioacetamide-induced liver fibrosis mouse model.

Conclusions: Thus, our findings indicate that Cho ameliorates HBx-induced HSC activation and liver fibrosis via inhibition of the mTOR and PPARs signaling pathways, suggesting that Cho is a potential therapeutic for chronic liver inflammation-mediated diseases.

大黄酚(Cho)是一种天然蒽醌类物质,具有诱导铁下垂和抗癌等生物学作用。乙型肝炎病毒X蛋白(HBx)对HBV复制至关重要。我们旨在确定hbx诱导的肝星状细胞(HSC)激活的关键途径,并表征Cho抗肝纤维化的潜在作用机制。方法:用FLAG(对照组)或FLAG-HBx (HBx组)转染HSC-T6细胞,通过RNA测序和Western blotting分析,评估HBx和Cho对特定分子靶点和信号通路的影响。结果:基因本体和通路分析表明,HBx靶向基因参与免疫应答、趋化因子和细胞因子活性、细胞-底物粘附、细胞外基质组织、生长因子结合、防御应答、抗原加工和递呈等。RNA-seq和Western blotting数据显示,hbx激活的HSC-T6细胞表现出哺乳动物雷帕霉素靶蛋白(mTOR)、磷酸化mTOR (p-mTOR)、S6、磷酸化S6 (p-S6)、过氧化物酶体增殖物激活受体(PPAR-α)、磷酸化PPAR-α (p-PPAR-α)、CYP27、α-平滑肌肌动蛋白(α-SMA)、结结组织生长因子(CTGF)、整合素-β1的上调表达,经Cho处理后表达逆转。这些结果也在hbx激活的HSC-T6和LX-2细胞模型和硫代乙酰胺诱导的肝纤维化小鼠模型中得到验证。结论:因此,我们的研究结果表明,Cho通过抑制mTOR和PPARs信号通路改善hbx诱导的HSC激活和肝纤维化,表明Cho是慢性肝脏炎症介导疾病的潜在治疗药物。
{"title":"Molecular Biological Mechanisms of Action of Chrysophanol in Hepatic Stellate Cells Activated by Hepatic B Virus X Based on Network Pharmacology.","authors":"Chih-Hung Lin, Ching-Feng Cheng, Yi-Shiou Chiou, Inga Wang, Chan-Yen Kuo","doi":"10.1159/000542355","DOIUrl":"10.1159/000542355","url":null,"abstract":"<p><strong>Introduction: </strong>Chrysophanol (Cho) is a natural anthraquinone with biological effects such as inducing ferroptosis and anticancer activity. The hepatitis B virus X protein (HBx) is essential for HBV replication. We aimed to identify the key pathways in HBx-induced hepatic stellate cell (HSC) activation and to characterize the potential mechanisms of action of Cho against liver fibrosis.</p><p><strong>Methods: </strong>HSC-T6 cells were transfected with FLAG (control group) or FLAG-HBx (HBx group), and RNA sequencing and Western blotting analysis were conducted to assess the effects of HBx and Cho on specific molecular targets and signaling pathways.</p><p><strong>Results: </strong>Gene ontology and pathway analyses indicated that the genes targeted by HBx participate in immunological responses, chemokine and cytokine activity, cell-substrate adhesion, extracellular matrix organization, growth factor binding, defense responses, and antigen processing and presentation. RNA-seq and Western blotting data revealed that HBx-activated HSC-T6 cells exhibited upregulated expression of mammalian target of rapamycin (mTOR), phosphorylated mTOR (p-mTOR), S6, phosphorylated S6 (p-S6), peroxisome proliferator-activated receptor (PPAR-α), phosphorylated-PPAR-α (p-PPAR-α), CYP27, α-smooth muscle actin (α-SMA), connective tissue growth factor (CTGF), and Integrin-β1, which was reversed after treatment with Cho. These results were also verified in a HBx-activated HSC-T6 and LX-2 cell model and thioacetamide-induced liver fibrosis mouse model.</p><p><strong>Conclusions: </strong>Thus, our findings indicate that Cho ameliorates HBx-induced HSC activation and liver fibrosis via inhibition of the mTOR and PPARs signaling pathways, suggesting that Cho is a potential therapeutic for chronic liver inflammation-mediated diseases.</p>","PeriodicalId":14547,"journal":{"name":"Intervirology","volume":"67 1","pages":"119-135"},"PeriodicalIF":3.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Clinical Outcomes of mRNA COVID-19 Vaccine in Pregnancy: A Systematic Review and Meta-Analysis. 妊娠期 mRNA COVID-19 疫苗的疗效和临床结果:系统回顾与元分析》。
IF 3.2 4区 医学 Q3 VIROLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-02 DOI: 10.1159/000538135
Antonio J Santimano, Raed M Al-Zoubi, Ahmad R Al-Qudimat, Mohamed B Al Darwish, Laxmi Kumari Ojha, Mohamed Amine Rejeb, Yasser Hamad, Malaz A Elrashid, Noorah M Ruxshan, Abdelfatteh El Omri, Hiba Bawadi, Maha A Al-Asmakh, Aksam Yassin, Omar M Aboumarzouk, Ahmad Zarour, Abdulla A Al-Ansari

Background: The world has witnessed one of the largest pandemics, dubbed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of December 2020, the USA alone reported 98,948 cases of coronavirus disease 2019 (COVID-19) infection during pregnancy, with 109 related maternal deaths. Current evidence suggests that unvaccinated pregnant women infected with SARS-CoV-2 are at a higher risk of experiencing complications related to COVID-19 compared to nonpregnant women. This review aimed to provide healthcare workers and non-healthcare workers with a comprehensive overview of the available information regarding the efficacy of vaccines in pregnant women.

Summary: We performed a systematic review and meta-analysis following PRISMA guidelines. The search through the database for articles published between December 2019 and October 2021 was performed. A comprehensive search was performed in PubMed, Scopus, and EMBASE databases for research publications published between December 2019 and October 2021. We focused on original research, case reports, case series, and vaccination side effect by authoritative health institutions. Phrases used for the Medical Subject Heading [MeSH] search included ("COVID-19" [MeSH]) or ("Vaccine" [MeSH]) and ("mRNA" [MeSH]) and ("Pregnant" [MeSH]). Eleven studies were selected and included, with a total of 46,264 pregnancies that were vaccinated with mRNA-containing lipid nanoparticle vaccine from Pfizer/BioNTech and Moderna during pregnancy. There were no randomized trials, and all studies were observational (prospective, retrospective, and cross-sectional). The mean maternal age was 32.2 years, and 98.7% of pregnant women received the Pfizer COVID-19 vaccination. The local and systemic adverse effects of the vaccination in pregnant women were analyzed and reported. The local adverse effects of the vaccination (at least 1 dose) such as local pain, swelling, and redness were reported in 32%, 5%, and 1%, respectively. The systemic adverse effects such as fatigue, headaches, new onset or worsening of muscle pain, chills, fever, and joint pains were also reported in 25%, 19%, 18%, 12%, 11%, and 8%, respectively. The average birthweight was 3,452 g. Among these pregnancies, 0.03% were stillbirth and 3.68% preterm (<37 weeks) births.

Key messages: The systemic side effect profile after administering the COVID-19 mRNA vaccine to pregnant women was similar to that in nonpregnant women. Maternal and fetal morbidity and mortality were lowered with the administration of either one or both the doses of the mRNA COVID-19 vaccination.

背景:世界上规模最大的流行病之一被称为严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)。截至 2020 年 12 月,仅美国就报告了 98,948 例孕期感染 COVID-19 的病例,其中 109 例孕产妇死亡。目前的证据表明,与非孕妇相比,未接种 SARS-CoV-2 疫苗的孕妇感染 SARS-CoV-2 后出现与冠状病毒病 2019(COVID-19)相关的并发症的风险更高。本综述旨在为医护人员和非医护人员提供有关孕妇疫苗疗效的现有信息的全面概述。摘要:我们按照系统性综述首选报告项目(PRISMA)和荟萃分析指南进行了系统性综述和荟萃分析。我们在数据库中检索了 2019 年 12 月至 2021 年 10 月间发表的文章。我们在 PubMed、Scopus 和 EMBASE 数据库中对 2019 年 12 月至 2021 年 10 月间发表的研究出版物进行了全面检索。我们重点关注权威医疗机构的原创研究、病例报告、系列病例和疫苗副作用。医学主题词表[MeSH]检索使用的词组包括(COVID-19"[MeSH])或 "疫苗"[MeSH])和 "mRNA"[MeSH])以及 "孕妇"[MeSH]。共有 46,264 名孕妇在怀孕期间接种了辉瑞/BioNTech 和 Moderna 公司生产的含 mRNA 的脂质纳米颗粒 (LNPs) 疫苗。所有研究均为观察性研究(前瞻性研究、回顾性研究和横断面研究)。孕妇的平均年龄为 32.2 岁,98.7% 的孕妇接种了辉瑞 COVD-19 疫苗。对孕妇接种疫苗后的局部和全身不良反应进行了分析和报告。接种疫苗(至少1剂)后出现局部疼痛、肿胀和发红等局部不良反应的比例分别为32%、5%和1%。报告的全身性不良反应包括疲劳、头痛、肌肉疼痛复发或加重、发冷、发热和关节痛,分别占 25%、19%、18%、12%、11% 和 8%。平均出生体重为 3452 克,死胎率为 0.03%,早产率为 3.68%:孕妇接种 COVID-19 mRNA 疫苗后的全身副作用与非孕妇相似。孕妇和胎儿的发病率和死亡率均有所降低。
{"title":"Efficacy and Clinical Outcomes of mRNA COVID-19 Vaccine in Pregnancy: A Systematic Review and Meta-Analysis.","authors":"Antonio J Santimano, Raed M Al-Zoubi, Ahmad R Al-Qudimat, Mohamed B Al Darwish, Laxmi Kumari Ojha, Mohamed Amine Rejeb, Yasser Hamad, Malaz A Elrashid, Noorah M Ruxshan, Abdelfatteh El Omri, Hiba Bawadi, Maha A Al-Asmakh, Aksam Yassin, Omar M Aboumarzouk, Ahmad Zarour, Abdulla A Al-Ansari","doi":"10.1159/000538135","DOIUrl":"10.1159/000538135","url":null,"abstract":"<p><strong>Background: </strong>The world has witnessed one of the largest pandemics, dubbed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of December 2020, the USA alone reported 98,948 cases of coronavirus disease 2019 (COVID-19) infection during pregnancy, with 109 related maternal deaths. Current evidence suggests that unvaccinated pregnant women infected with SARS-CoV-2 are at a higher risk of experiencing complications related to COVID-19 compared to nonpregnant women. This review aimed to provide healthcare workers and non-healthcare workers with a comprehensive overview of the available information regarding the efficacy of vaccines in pregnant women.</p><p><strong>Summary: </strong>We performed a systematic review and meta-analysis following PRISMA guidelines. The search through the database for articles published between December 2019 and October 2021 was performed. A comprehensive search was performed in PubMed, Scopus, and EMBASE databases for research publications published between December 2019 and October 2021. We focused on original research, case reports, case series, and vaccination side effect by authoritative health institutions. Phrases used for the Medical Subject Heading [MeSH] search included (\"COVID-19\" [MeSH]) or (\"Vaccine\" [MeSH]) and (\"mRNA\" [MeSH]) and (\"Pregnant\" [MeSH]). Eleven studies were selected and included, with a total of 46,264 pregnancies that were vaccinated with mRNA-containing lipid nanoparticle vaccine from Pfizer/BioNTech and Moderna during pregnancy. There were no randomized trials, and all studies were observational (prospective, retrospective, and cross-sectional). The mean maternal age was 32.2 years, and 98.7% of pregnant women received the Pfizer COVID-19 vaccination. The local and systemic adverse effects of the vaccination in pregnant women were analyzed and reported. The local adverse effects of the vaccination (at least 1 dose) such as local pain, swelling, and redness were reported in 32%, 5%, and 1%, respectively. The systemic adverse effects such as fatigue, headaches, new onset or worsening of muscle pain, chills, fever, and joint pains were also reported in 25%, 19%, 18%, 12%, 11%, and 8%, respectively. The average birthweight was 3,452 g. Among these pregnancies, 0.03% were stillbirth and 3.68% preterm (&lt;37 weeks) births.</p><p><strong>Key messages: </strong>The systemic side effect profile after administering the COVID-19 mRNA vaccine to pregnant women was similar to that in nonpregnant women. Maternal and fetal morbidity and mortality were lowered with the administration of either one or both the doses of the mRNA COVID-19 vaccination.</p>","PeriodicalId":14547,"journal":{"name":"Intervirology","volume":" ","pages":"40-54"},"PeriodicalIF":3.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11006275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140021746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Outbreak of Acute Hemorrhagic Conjunctivitis Caused by Coxsackievirus A24 in Eastern Uttar Pradesh, India 2023. 2023 年印度北方邦东部爆发柯萨奇病毒 A24 引起的急性出血性结膜炎。
IF 3.2 4区 医学 Q3 VIROLOGY Pub Date : 2024-01-01 Epub Date: 2024-10-22 DOI: 10.1159/000540952
Sthita Pragnya Behera, Nalini Mishra, Ramyash Yadav, Aishwarya Shukla, Moni Kumari, Sonal Rajput, Imbisat Fatma, Ashutosh Tiwari, Prashansha Srivastava, Shashikant Tiwari, Rajeev Singh, Satish S Ranawade, Manoj Murhekar, Gaurav Raj Dwivedi

Introduction: Acute hemorrhagic conjunctivitis (AHC) outbreaks are caused mostly by viruses. During July-August 2023, there was a sudden spike in acute hemorrhage conjunctivitis cases in Eastern Uttar Pradesh, India. To identify the etiological and gain molecular epidemiology of the agent, the study was conducted.

Methodology: Conjunctival swabs were collected from patients (n = 128) with presumed acute hemorrhage conjunctivitis visiting two tertiary care hospitals.

Results: Enteroviruses infection was identified in 96 (75%) patients. In these patients, coxsackievirus A24 (CV-A24) infection was further confirmed by targeting the genetic regions of 3C protease and VP1. Furthermore, the study established the outbreak was caused by the genotype IV of CV-A24 with the highest genetic similarity with CV-A24 reported from Northeast India, China, and Pakistan circulating during the same period. The comparison of our study sequences with earlier Indian outbreak strains (2007) revealed four amino acid substitutions at the 3C region ("S21N," "V30I," "S66I," and "V75I") and three non-synonymous mutations at the VP1 region ("L16I," "P21S," and "N301D").

Conclusion: The study findings revealed that the AHC outbreak was caused by genotype IV of CV-A24 in this region. Molecular identification accompanied by phylogenetic analysis will be useful in studying the enterovirus epidemiology associated with AHC outbreaks.

导言:急性出血性结膜炎(AHC)的爆发主要是由病毒引起的。2023 年 7 月至 8 月期间,印度北方邦东部的急性出血性结膜炎病例突然激增。为了确定病原体并获得分子流行病学,我们开展了这项研究:方法:从两家三级医院就诊的推测患有急性出血性结膜炎的患者(n = 128)中采集结膜拭子:结果:96 名(75%)患者确定感染了肠道病毒。结果:在 96 名(75%)患者中发现了肠道病毒感染,其中柯萨奇病毒 A24(CV-A24)感染是通过靶向 3C 蛋白酶和 VP1 基因区进一步确认的。此外,研究还确定疫情是由 CV-A24 基因型 IV 引起的,该基因型与同期在印度东北部、中国和巴基斯坦流行的 CV-A24 基因型相似度最高。将我们的研究序列与早期印度疫情株(2007 年)进行比较,发现 3C 区有四个氨基酸置换("S21N"、"V30I"、"S66I "和 "V75I"),VP1 区有三个非同义突变("L16I"、"P21S "和 "N301D"):研究结果表明,该地区爆发的 AHC 是由 CV-A24 基因型 IV 引起的。分子鉴定和系统发育分析将有助于研究与 AHC 爆发相关的肠道病毒流行病学。
{"title":"An Outbreak of Acute Hemorrhagic Conjunctivitis Caused by Coxsackievirus A24 in Eastern Uttar Pradesh, India 2023.","authors":"Sthita Pragnya Behera, Nalini Mishra, Ramyash Yadav, Aishwarya Shukla, Moni Kumari, Sonal Rajput, Imbisat Fatma, Ashutosh Tiwari, Prashansha Srivastava, Shashikant Tiwari, Rajeev Singh, Satish S Ranawade, Manoj Murhekar, Gaurav Raj Dwivedi","doi":"10.1159/000540952","DOIUrl":"10.1159/000540952","url":null,"abstract":"<p><strong>Introduction: </strong>Acute hemorrhagic conjunctivitis (AHC) outbreaks are caused mostly by viruses. During July-August 2023, there was a sudden spike in acute hemorrhage conjunctivitis cases in Eastern Uttar Pradesh, India. To identify the etiological and gain molecular epidemiology of the agent, the study was conducted.</p><p><strong>Methodology: </strong>Conjunctival swabs were collected from patients (n = 128) with presumed acute hemorrhage conjunctivitis visiting two tertiary care hospitals.</p><p><strong>Results: </strong>Enteroviruses infection was identified in 96 (75%) patients. In these patients, coxsackievirus A24 (CV-A24) infection was further confirmed by targeting the genetic regions of 3C protease and VP1. Furthermore, the study established the outbreak was caused by the genotype IV of CV-A24 with the highest genetic similarity with CV-A24 reported from Northeast India, China, and Pakistan circulating during the same period. The comparison of our study sequences with earlier Indian outbreak strains (2007) revealed four amino acid substitutions at the 3C region (\"S21N,\" \"V30I,\" \"S66I,\" and \"V75I\") and three non-synonymous mutations at the VP1 region (\"L16I,\" \"P21S,\" and \"N301D\").</p><p><strong>Conclusion: </strong>The study findings revealed that the AHC outbreak was caused by genotype IV of CV-A24 in this region. Molecular identification accompanied by phylogenetic analysis will be useful in studying the enterovirus epidemiology associated with AHC outbreaks.</p>","PeriodicalId":14547,"journal":{"name":"Intervirology","volume":"67 1","pages":"106-113"},"PeriodicalIF":3.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Value of Serum miR-106a in the Diagnosis and Prognosis of Human Papillomavirus-Positive Cervical Cancer. 血清 miR-106a 在人类乳头瘤病毒阳性宫颈癌诊断和预后中的临床价值
IF 4.6 4区 医学 Q3 VIROLOGY Pub Date : 2023-01-01 Epub Date: 2023-01-16 DOI: 10.1159/000528806
Xiaoyan Rao, Jie Jiang, Yifeng Wang, Xueli Ma, Shuxia Liu

Introduction: Cervical cancer (CC) is a prevailing malignant tumor in women, mainly caused by human papillomavirus (HPV) infection. This study investigated miR-106a expression in the serum of HPV-positive CC patients and estimated its value in diagnosis and prognosis.

Methods: We enrolled 120 CC patients as study subjects, with another 80 healthy women as controls. Clinical baseline data and clinicopathological indexes including age, tumor size, differentiation degree, FIGO stage, lymph node metastasis, and squamous cell carcinoma antigen (SCC-Ag) were recorded. Serum miR-106a expression was measured using reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic curve was employed to estimate the efficacy of miR-106a in diagnosing CC or HPV-positive CC. Under a 5-year follow-up, patient survival was recorded, and the impact of miR-106a on overall survival rate was analyzed by the Kaplan-Meier method. The logistic regression model was used to analyze whether miR-106a was an independent prognostic factor for HPV infection in CC patients.

Results: Serum miR-106a was upregulated in CC patients and the level >1.365 assisted the CC diagnosis. miR-106a expression in HPV-positive CC patients was elevated relative to HPV-negative CC patients, and serum miR-106a level >1.300 distinguishing HPV positive and HPV negative. HPV positivity was linked with tumor differentiation degree, FIGO stage, lymph node metastasis, and SCC-Ag in CC patients, but not with age and tumor size. High expression of miR-106a in HPV-positive CC patients increased the risk of poor prognosis, and miR-106a expression is an independent prognostic factor for HPV infection in CC patients.

Conclusion: High expression of miR-106a assists in the diagnosis of HPV-positive CC and predicts poor prognosis.

导言宫颈癌(CC)是女性常见的恶性肿瘤,主要由人乳头瘤病毒(HPV)感染引起。本研究调查了 HPV 阳性 CC 患者血清中 miR-106a 的表达情况,并估计了其在诊断和预后方面的价值:我们招募了 120 名 CC 患者作为研究对象,另外 80 名健康女性作为对照。记录临床基线数据和临床病理指标,包括年龄、肿瘤大小、分化程度、FIGO 分期、淋巴结转移和鳞状细胞癌抗原(SCC-Ag)。采用反转录定量聚合酶链反应测定血清 miR-106a 的表达。采用接收者操作特征曲线来估计 miR-106a 在诊断 CC 或 HPV 阳性 CC 中的有效性。在为期 5 年的随访中,记录了患者的存活率,并采用 Kaplan-Meier 法分析了 miR-106a 对总存活率的影响。采用逻辑回归模型分析miR-106a是否是CC患者HPV感染的独立预后因素:HPV阳性CC患者的miR-106a表达相对于HPV阴性CC患者升高,血清miR-106a水平为1.300,可区分HPV阳性和HPV阴性。HPV阳性与CC患者的肿瘤分化程度、FIGO分期、淋巴结转移和SCC-Ag有关,但与年龄和肿瘤大小无关。HPV阳性CC患者中miR-106a的高表达增加了预后不良的风险,miR-106a的表达是CC患者HPV感染的独立预后因素:结论:miR-106a的高表达有助于HPV阳性CC的诊断,并可预测不良预后。
{"title":"Clinical Value of Serum miR-106a in the Diagnosis and Prognosis of Human Papillomavirus-Positive Cervical Cancer.","authors":"Xiaoyan Rao, Jie Jiang, Yifeng Wang, Xueli Ma, Shuxia Liu","doi":"10.1159/000528806","DOIUrl":"10.1159/000528806","url":null,"abstract":"<p><strong>Introduction: </strong>Cervical cancer (CC) is a prevailing malignant tumor in women, mainly caused by human papillomavirus (HPV) infection. This study investigated miR-106a expression in the serum of HPV-positive CC patients and estimated its value in diagnosis and prognosis.</p><p><strong>Methods: </strong>We enrolled 120 CC patients as study subjects, with another 80 healthy women as controls. Clinical baseline data and clinicopathological indexes including age, tumor size, differentiation degree, FIGO stage, lymph node metastasis, and squamous cell carcinoma antigen (SCC-Ag) were recorded. Serum miR-106a expression was measured using reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic curve was employed to estimate the efficacy of miR-106a in diagnosing CC or HPV-positive CC. Under a 5-year follow-up, patient survival was recorded, and the impact of miR-106a on overall survival rate was analyzed by the Kaplan-Meier method. The logistic regression model was used to analyze whether miR-106a was an independent prognostic factor for HPV infection in CC patients.</p><p><strong>Results: </strong>Serum miR-106a was upregulated in CC patients and the level &gt;1.365 assisted the CC diagnosis. miR-106a expression in HPV-positive CC patients was elevated relative to HPV-negative CC patients, and serum miR-106a level &gt;1.300 distinguishing HPV positive and HPV negative. HPV positivity was linked with tumor differentiation degree, FIGO stage, lymph node metastasis, and SCC-Ag in CC patients, but not with age and tumor size. High expression of miR-106a in HPV-positive CC patients increased the risk of poor prognosis, and miR-106a expression is an independent prognostic factor for HPV infection in CC patients.</p><p><strong>Conclusion: </strong>High expression of miR-106a assists in the diagnosis of HPV-positive CC and predicts poor prognosis.</p>","PeriodicalId":14547,"journal":{"name":"Intervirology","volume":" ","pages":"54-62"},"PeriodicalIF":4.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9471571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of MicroRNA Expression Pattern (miR-28, miR-181a, miR-34a, and miR-31) in Patients with COVID-19 Admitted to ICU and Diabetic COVID-19 Patients. 评估入住重症监护室的 COVID-19 患者和糖尿病 COVID-19 患者的 MicroRNA 表达模式(miR-28、miR-181a、miR-34a 和 miR-31)。
IF 4.6 4区 医学 Q3 VIROLOGY Pub Date : 2023-01-01 Epub Date: 2023-03-07 DOI: 10.1159/000529985
AliReza Khatami, Mohammad Taghizadieh, Javid Sadri Nahand, Mohammad Karimzadeh, Seyed Jalal Kiani, Khadijeh Khanaliha, Saeed Kalantari, Sara Chavoshpour, Hamed Mirzaei, Tahereh Donyavi, Farah Bokharaei-Salim

Introduction: MicroRNAs, or miRNAs, with regulatory performance in inflammatory responses and infection are the prevalent manifestations of severe coronavirus disease (COVID-19). This study aimed to evaluate whether PBMC miRNAs are diagnostic biomarkers to screen the ICU COVID-19 and diabetic COVID-19 subjects.

Methods: Candidate miRNAs were selected through previous studies, and then the PBMC levels of selected miRNAs (miR-28, miR-31, miR-34a, and miR-181a) were measured via quantitative reverse transcription PCR. The diagnostic value of miRNAs was determined by the receiver operating characteristic (ROC) curve. The bioinformatics analysis was utilized to predict the DEM genes and relevant bio-functions.

Results: The COVID-19 patients admitted to ICU had significantly greater levels of selected miRNAs compared to non-hospitalized COVID-19 and healthy people. Besides, the mean miR-28 and miR-34a expression levels in the diabetic COVID-19 group were significantly upregulated when compared with the non-diabetic COVID-19 group. ROC analyses demonstrated the role of miR-28, miR-34a, and miR-181a as new biomarkers to discriminate the non-hospitalized COVID-19 group from the COVID-19 patients admitted to ICU samples, and also miR-34a can probably act as a useful biomarker for screening diabetic COVID-19 patients. Using bioinformatics analyses, we found the performance of target transcripts in many bioprocesses and diverse metabolic routes such as the regulation of multiple inflammatory parameters.

Discussion: The difference in miRNA expression patterns between the studied groups suggested that miR-28, miR-34a, and miR-181a could be helpful as potent biomarkers for diagnosing and controlling COVID-19.

导言:在炎症反应和感染中具有调控功能的微RNA(或称miRNA)是严重冠状病毒病(COVID-19)的普遍表现。本研究旨在评估 PBMC miRNAs 是否是筛选 ICU COVID-19 和糖尿病 COVID-19 受试者的诊断生物标志物:方法:通过以往的研究筛选出候选miRNA,然后通过反转录PCR定量检测所选miRNA(miR-28、miR-31、miR-34a和miR-181a)的PBMC水平。miRNA 的诊断价值由接收者操作特征曲线(ROC)决定。利用生物信息学分析预测DEM基因和相关生物功能:结果:与非住院的COVID-19患者和健康人相比,入住重症监护室的COVID-19患者所选miRNA的水平明显更高。此外,与非糖尿病 COVID-19 组相比,糖尿病 COVID-19 组的平均 miR-28 和 miR-34a 表达水平明显升高。ROC分析表明,miR-28、miR-34a和miR-181a是区分非住院COVID-19组和入住ICU样本的COVID-19患者的新生物标记物,而且miR-34a可能是筛查糖尿病COVID-19患者的有用生物标记物。通过生物信息学分析,我们发现了目标转录物在许多生物过程和多种代谢途径中的表现,如调节多种炎症参数:讨论:研究组之间 miRNA 表达模式的差异表明,miR-28、miR-34a 和 miR-181a 可作为诊断和控制 COVID-19 的有效生物标志物。
{"title":"Evaluation of MicroRNA Expression Pattern (miR-28, miR-181a, miR-34a, and miR-31) in Patients with COVID-19 Admitted to ICU and Diabetic COVID-19 Patients.","authors":"AliReza Khatami, Mohammad Taghizadieh, Javid Sadri Nahand, Mohammad Karimzadeh, Seyed Jalal Kiani, Khadijeh Khanaliha, Saeed Kalantari, Sara Chavoshpour, Hamed Mirzaei, Tahereh Donyavi, Farah Bokharaei-Salim","doi":"10.1159/000529985","DOIUrl":"10.1159/000529985","url":null,"abstract":"<p><strong>Introduction: </strong>MicroRNAs, or miRNAs, with regulatory performance in inflammatory responses and infection are the prevalent manifestations of severe coronavirus disease (COVID-19). This study aimed to evaluate whether PBMC miRNAs are diagnostic biomarkers to screen the ICU COVID-19 and diabetic COVID-19 subjects.</p><p><strong>Methods: </strong>Candidate miRNAs were selected through previous studies, and then the PBMC levels of selected miRNAs (miR-28, miR-31, miR-34a, and miR-181a) were measured via quantitative reverse transcription PCR. The diagnostic value of miRNAs was determined by the receiver operating characteristic (ROC) curve. The bioinformatics analysis was utilized to predict the DEM genes and relevant bio-functions.</p><p><strong>Results: </strong>The COVID-19 patients admitted to ICU had significantly greater levels of selected miRNAs compared to non-hospitalized COVID-19 and healthy people. Besides, the mean miR-28 and miR-34a expression levels in the diabetic COVID-19 group were significantly upregulated when compared with the non-diabetic COVID-19 group. ROC analyses demonstrated the role of miR-28, miR-34a, and miR-181a as new biomarkers to discriminate the non-hospitalized COVID-19 group from the COVID-19 patients admitted to ICU samples, and also miR-34a can probably act as a useful biomarker for screening diabetic COVID-19 patients. Using bioinformatics analyses, we found the performance of target transcripts in many bioprocesses and diverse metabolic routes such as the regulation of multiple inflammatory parameters.</p><p><strong>Discussion: </strong>The difference in miRNA expression patterns between the studied groups suggested that miR-28, miR-34a, and miR-181a could be helpful as potent biomarkers for diagnosing and controlling COVID-19.</p>","PeriodicalId":14547,"journal":{"name":"Intervirology","volume":" ","pages":"63-76"},"PeriodicalIF":4.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9728263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Broad Antiviral Spectrum of Glycyrrhizic Acid for Human and Veterinary Medicine: Reality or Fiction? 用于人类和兽医的甘草酸的广泛抗病毒谱:现实还是虚构?
IF 4.6 4区 医学 Q3 VIROLOGY Pub Date : 2023-01-01 Epub Date: 2022-12-01 DOI: 10.1159/000528198
Gilberto García-Salazar, Zaida Urbán-Morlán, Susana Mendoza-Elvira, David Quintanar-Guerrero, Sandra Mendoza

Background: Emerging virus infections provoke health problems in people and animals, which generate social and economic issues worldwide. This has spurred the search for new pharmacological strategies to confront them.

Summary: The purpose of this review is to draw the reader's attention to pharmacological evaluations of glycyrrhizic acid (GA) and its analogs on the broad range of viruses known in human and veterinary medicine. GA is the main water-soluble constituent extracted from the roots of plants from the genus Glycyrrhiza, commonly known as licorice root. It has long been used due to its broad spectrum of bioactivities, including anti-inflammatory, antiulcer, and antitumor properties. It has also been proposed as an antiviral agent. Medicines derived from GA are currently being used to combat acute and chronic hepatitis and herpes viruses.

Key messages: This review suggests that GA could be a new broad-spectrum antiviral due to its ability to inhibit DNA or RNA viruses both in vitro and in vivo. GA could be a potential drug for preventing and/or treating various viral diseases.

背景:新出现的病毒感染引发了人类和动物的健康问题,造成了全球范围内的社会和经济问题。摘要:本综述旨在提请读者注意甘草酸(GA)及其类似物对人类和兽医已知的多种病毒的药理评估。甘草酸是从甘草属植物(俗称甘草根)的根中提取的主要水溶性成分。由于它具有广泛的生物活性,包括抗炎、抗溃疡和抗肿瘤等特性,长期以来一直被人们使用。它还被认为是一种抗病毒剂。从天麻中提取的药物目前正被用于抗击急慢性肝炎和疱疹病毒:本综述认为,由于天麻具有体外和体内抑制 DNA 或 RNA 病毒的能力,因此可以成为一种新的广谱抗病毒药物。GA可能是预防和/或治疗各种病毒性疾病的潜在药物。
{"title":"Broad Antiviral Spectrum of Glycyrrhizic Acid for Human and Veterinary Medicine: Reality or Fiction?","authors":"Gilberto García-Salazar, Zaida Urbán-Morlán, Susana Mendoza-Elvira, David Quintanar-Guerrero, Sandra Mendoza","doi":"10.1159/000528198","DOIUrl":"10.1159/000528198","url":null,"abstract":"<p><strong>Background: </strong>Emerging virus infections provoke health problems in people and animals, which generate social and economic issues worldwide. This has spurred the search for new pharmacological strategies to confront them.</p><p><strong>Summary: </strong>The purpose of this review is to draw the reader's attention to pharmacological evaluations of glycyrrhizic acid (GA) and its analogs on the broad range of viruses known in human and veterinary medicine. GA is the main water-soluble constituent extracted from the roots of plants from the genus Glycyrrhiza, commonly known as licorice root. It has long been used due to its broad spectrum of bioactivities, including anti-inflammatory, antiulcer, and antitumor properties. It has also been proposed as an antiviral agent. Medicines derived from GA are currently being used to combat acute and chronic hepatitis and herpes viruses.</p><p><strong>Key messages: </strong>This review suggests that GA could be a new broad-spectrum antiviral due to its ability to inhibit DNA or RNA viruses both in vitro and in vivo. GA could be a potential drug for preventing and/or treating various viral diseases.</p>","PeriodicalId":14547,"journal":{"name":"Intervirology","volume":" ","pages":"41-53"},"PeriodicalIF":4.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9115688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Intervirology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1